MCRBHIGH SIGNALFINANCIAL10-K

MCRB underwent a dramatic financial transformation with a massive share reduction from 174M to 9.6M shares outstanding, likely indicating a significant reverse stock split or restructuring transaction.

The 95% reduction in outstanding shares combined with improved profitability and positive operating cash flow suggests a major corporate restructuring that has strengthened the company's financial position. However, the doubling of total debt to $110M and continued going concern warnings indicate the company still faces substantial financial challenges despite these improvements.

Comparing 2026-03-12 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

MCRB showed remarkable financial improvement with net income swinging from $136K to $5.7M and operating cash flow turning positive at $1.1M from negative $148.6M, while R&D expenses declined 24% to $49.1M. The balance sheet strengthened significantly with stockholders' equity surging 221% to $44.2M, cash increasing 49% to $45.8M, and current liabilities falling 53% to $19.3M. However, total debt doubled to $110M, suggesting the financial improvements may have come through debt financing or a major transaction that restructured the company's capital structure.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+4088.2%
$136K→$5.7M

Net income grew 4088.2% — bottom-line growth signals improving overall business health.

Stockholders Equity
Balance Sheet
+220.8%
$13.8M→$44.2M

Equity base grew 220.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Debt
Balance Sheet
+120%
$50.0M→$110.0M

Debt increased 120% — substantial leverage increase; assess whether deployed for growth or covering losses.

Operating Cash Flow
Cash Flow
+100.8%
-$148.6M→$1.1M

Operating cash flow surged 100.8% — exceptional cash generation, highest quality earnings signal.

Current Liabilities
Balance Sheet
-53.1%
$41.2M→$19.3M

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
+48.6%
$30.8M→$45.8M

Cash position surged 48.6% — strong cash generation or capital raise providing significant financial cushion.

Capital Expenditure
Cash Flow
-33.7%
$380K→$252K

Capex reduced 33.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
+27.7%
$38.7M→$49.4M

Current assets grew 27.7% — improving short-term liquidity or inventory/receivables build.

Total Liabilities
Balance Sheet
-25.4%
$126.0M→$94.0M

Liabilities reduced 25.4% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-24.1%
$64.6M→$49.1M

R&D spending cut 24.1% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-13
ADDED
As of March 6, 2026 there wer e 9,586,298 shares of the registrant s common stock, par value $0.001 per share, outstanding.
The principal risks and uncertainties affecting our business include the following: We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.
We will need additional funding in order to advance development of our product candidates (including to conduct the Phase 2 study of SER-155 in allo-HSCT) and commercialize our product candidates, if approved.
If we are unable to raise capital or secure a partnership or other business development transaction, we could be required to implement further cost-reduction measures, reduce or delay our product development programs or any potential future commercialization efforts, or pursue other alternatives, which could include seeking relief under the U.S Bankruptcy Code or winding down our operations.
3 The total amount of the Milestone Payments (as defined herein) we may receive from the Transaction is subject to various risks and uncertainties.
+7 more — sign up free →
REMOVED
As of March 7, 2025 there were 174,358,753 shares of the registrant s common stock, par value $0.001 per share, outstanding.
The principal risks and uncertainties affecting our business include the following: We will need additional funding in order to advance development of our product candidates and commercialize our product candidates, if approved.
If we are unable to raise capital or secure a partnership when needed, we could be forced to delay, reduce or eliminate our product development programs or any potential future commercialization efforts.
We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.
The total amount of the Second Installment Payment (as defined herein) and Milestone Payments (as defined herein) we may receive from the Transaction, and the amounts payable or due under the Profit Sharing Payments (as defined herein), are subject to various risks and uncertainties.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →